Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Linden Thomas Advisory Services LLC

Linden Thomas Advisory Services LLC trimmed its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 2.4% in the 4th quarter, HoldingsChannel reports. The firm owned 41,653 shares of the biopharmaceutical company’s stock after selling 1,037 shares during the period. Linden Thomas Advisory Services LLC’s holdings in Xencor were worth $884,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in XNCR. AE Wealth Management LLC purchased a new position in Xencor in the 3rd quarter valued at $502,000. SG Americas Securities LLC purchased a new position in Xencor in the 3rd quarter valued at about $875,000. Raymond James Financial Services Advisors Inc. grew its position in shares of Xencor by 4.5% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 16,781 shares of the biopharmaceutical company’s stock valued at $338,000 after purchasing an additional 718 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Xencor by 24.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,575 shares of the biopharmaceutical company’s stock valued at $253,000 after acquiring an additional 2,431 shares during the last quarter. Finally, BluePath Capital Management LLC purchased a new position in Xencor during the third quarter worth approximately $31,000.

Insider Buying and Selling

In other news, VP John R. Desjarlais sold 54,108 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $19.38, for a total transaction of $1,048,613.04. Following the completion of the transaction, the vice president now owns 161,675 shares of the company’s stock, valued at $3,133,261.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, VP John R. Desjarlais sold 54,108 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $19.38, for a total value of $1,048,613.04. Following the sale, the vice president now owns 161,675 shares of the company’s stock, valued at $3,133,261.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP John R. Desjarlais sold 1,280 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $23.50, for a total value of $30,080.00. Following the completion of the sale, the vice president now directly owns 186,433 shares in the company, valued at approximately $4,381,175.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 101,351 shares of company stock valued at $2,152,417. 4.97% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Mizuho cut their price target on shares of Xencor from $59.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, January 22nd. Piper Sandler reiterated a “neutral” rating and set a $24.00 target price (down previously from $37.00) on shares of Xencor in a research note on Wednesday, February 28th. Royal Bank of Canada reiterated an “outperform” rating and issued a $32.00 target price on shares of Xencor in a research note on Wednesday, February 28th. BTIG Research decreased their price objective on Xencor from $56.00 to $38.00 and set a “buy” rating for the company in a report on Tuesday, April 16th. Finally, BMO Capital Markets lowered their target price on shares of Xencor from $38.00 to $34.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 28th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $36.00.

Xencor Trading Up 1.1 %

XNCR opened at $19.23 on Friday. The stock has a 50-day moving average of $22.10 and a 200-day moving average of $20.34. The company has a current ratio of 7.36, a quick ratio of 7.36 and a debt-to-equity ratio of 0.02. Xencor, Inc. has a 52-week low of $16.49 and a 52-week high of $28.96.

Xencor (NASDAQ:XNCR) last announced its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of $0.36 by ($0.67). The business had revenue of $44.70 million for the quarter, compared to the consensus estimate of $77.63 million. Xencor had a negative net margin of 74.90% and a negative return on equity of 18.67%. Xencor’s revenue for the quarter was up 106.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.20) EPS. Equities analysts forecast that Xencor, Inc. will post -3.25 earnings per share for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.